Johannes DE HAARD,Samson FUNG,Nicolas LEUPIN,Adrian OCHSENBEIN,Carsten RIETHER,Luc VAN ROMPAEY
申请号：
US16719220
公开号：
US20200222532A1
申请日:
2019.12.18
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.
